Imugene (ASX:IMU) Presentation, FNN Investor Event, October 2018, Sydney

Company Presentations

Imugene Limited (ASX:IMU) Managing Director & CEO, Leslie Chong presents on the company's trial progress with its lead HER-Vaxx cancer vaccine, advantages of B-cell vaccines and strengthened scientific board at FNN's Investor Event.

Key points:

  • Develops vaccines to boost the immune system to attack cancer cells
  • Harnessing B-cells for cancer immunotherapy
  • Broadened clinical programs globally, including U.S. and European centres
  • HER-Vaxx milestones of Phase 1b recruitment completed
  • Phase 2 activity commenced
  • B-Vaxx Phase 2 ongoing
  • KEY-Vaxx pre-clinical work started
  • Synergistic technology licensed from Ohio State University and The Mayo Clinic

For more watch Managing Director and CEO, Leslie Chong present.